KEDİLERDE ANTİVİRAL TEDAVİ

Year 2021, Volume: 30 Issue: 2, 215 - 220, 15.09.2021

Yaprak Durmuş , Handan Hilal Arslan Yavuz

https://doi.org/10.34108/eujhs.907880

Abstract

Koronavirüs pandemisini yaşadığımız şu günlerde viral enfeksiyonların yaşam dinamiklerimizi nasıl değiştirebildiğini ve yıkıcı gücünü bir kez daha fark etmiş bulunmaktayız. Viral hastalıklar, insanoğlu ve çevresindeki bütün canlılar için dünya var olduğundan bu yana epidemi ve pandemilere yol açarak hayati tehlike oluşturmuştur. Milyonlarca canlının ölümüne veya itlafına yol açan bu salgınlar, korunma ve tedavi gereksinimlerini de beraberlerinde getirmiştir. İnsan ve hayvanlardaki bazı viral hastalıklar üzerine etkili antiviral tedavi alternatifleri olmakla beraber hala tedavi seçenekleri oldukça sınırlıdır. Bu makalede veteriner hekimlikte kullanılabilecek in vivo çalışması yapılmış antiviral ajanların bir bölümü kedilerdeki viral hastalıklar üzerinden değerlendirilmiştir.

Keywords

antiviral ilaçlar, kedi, tedavi, viral hastalıklar

ANTIVIRAL TREATMENT IN CATS

Abstract

In these days when we are experiencing the coronavirus pandemic, we have once again realized how viral infections can change our life dynamics and their destructive power. Viral diseases have been life-threatening by causing epidemics and pandemics for humans and other organisms since the world existed. These outbreaks, which caused the death or culling of millions of animals, brought the need for protection and treatment. Although there are effective antiviral treatment alternatives for some viral diseases in humans and animals, treatment options are still very limited. In this article, some of antiviral agents that can be used in veterinary medicine and have been studied in vivo were evaluated over viral diseases in cats.

Keywords

Antiviral drugs, cat, treatment, viral diseases

References

• Aktaş F. Antiviral ajanlar. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 1997; 4:227-235.
• Bule M, Khan F, Niaz K. Antivirals: Past, present and future. In: Malik YS, Singh RK, Yadav MP (eds), Recent advances in animal virology. Springer, India 2019; pp 425-441.
• Kaya S. Veteriner Farmakoloji Kitabı (5. Baskı), Cilt 2. Medisan Yayınları, Ankara 2013; ss 653-665.
• Hartmann K, Wooding A, Bergmann M. Efficacy of antiviral drugs against feline immunodeficiency virus. Vet Sci 2015; 2:456-476.
• Küçük A, Yıldırım Y. Antiviral ilaçlar. Etlik Vet Mikrobiyol Derg 2019; 30(1):100-108.
• Davis JL., Maxwell L. Veterinary Pharmacology and Therapeutics In: Riviere and Papich (eds), Wiley-Blackwell, 2018, pp 1010-1020.
• Bisset LR, Lutz H, Böni J, et al. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication. Antivir Res 2002; 53:35-45.
• Radford A. Antiviral therapy in cats. What works and what doesn't. World Small Animal Veterinary Association World Congress Proceedings 2006, https://www.vin.com/apputil/content/defaultadv1.aspx?id=3859012&pid=11223
• Li SF, Zhao FRS, Jun-jun X. et al. Interferon-omega: Current status in clinical applications. International Immunopharmacology 2017; 52:253–260.
• Hartmann K. Feline Leukemia Virus Infection, In: Greene CE (eds), Infectious diseases of the dog and cat (4th ed). Elsevier, Athens, Georgia 2012; pp 108-136.
• Maggs DJ. Update on pathogenesis, diagnosis, and treatment of feline herpesvirus type 1. Clinical Techniques in Small Animal Practice 2005; 20:94-101.
• Maggs DJ. Antiviral therapy for feline herpesvirus infections. Vet Clin Small Anim 2010; 40:1055-1062.
• El-Gallad SB. Investigation of the antiviral effect of ribavirin and acyclovir on canine distemper and infectious canine hepatitis viruses. Suez Canal Vet Med J. 2008; 13:555–563.
• De Clercq E, Li G. Approved antiviral drugs over the last 50 years. Clin Microbiol Rev 2016; 29:695-747.
• Bentz BG, Maxwell LK, Erkert RS, et al. Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. J Vet Intern Med 2006; 20:589-594.
• Pedersen NC. An update on feline infectious peritonitis: Diagnostics and therapeutics. The Veterinary Journal 2014; 201:133–141.
• Legendre AM, Kuritz T, Galyon G et al. Polyprenyl immunostimulant treatment of cats with presumptive non-effusive feline infectious peritonitis in a field study Front Vet Sci 2017; 4:7.
• Addie DD. Feline coronavirus infections. In: Greene CE (eds), Infectious diseases of the dog and cat (4th ed). Elsevier, Athens, Georgia 2012; pp 92-108.
• Legendre AM, Bartges JW. Effect of polyprenyl immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis. ACVN J. Feline Med Surg 2009; 11(8):624-626.
• Hsieh LE, Lin CN, Su BL et al. Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus. Antivir Res 2010; 88:25-30.
• Doki T, Tarusawa T, Hohdatsu T, Takano T. In vivo antiviral effects of U18666A against type I feline infectious peritonitis virus. Pathogens 2020; (9):67.
• Addiea DD, Curranb S, Bellinic F et al. Mutian®X stopped faecal feline coronavirus shedding by naturally infected cats. Res Vet Sci 2020; 130:222-229.
• Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Molly Liepnieks M, Liu H. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg 2019; 21(4):271–281.
• Stuetzer B, Hartmann K. Feline parvovirus infection and associated diseases. The Vet J 2014; 20:150-155.
• Hartmann K. Feline upper respiratory tract infections–current treatment strategies. Thai J Vet Med Suppl 2017; 47:105-107.
• Chen K, Liu J, Cao X. Regulation of type I interferon signaling in immunity andinflammation: A comprehensive review. J Autoimmun 2017; 83:1-11.
• Pfaff A. Feline upper respiratory complex. In: Drobatz KJ, Hopper K, Rozanski EA, Deborah C (eds). Silverstein Textbook of Small Animal Emergency Medicine. Wiley and Sons Inc 2019; pp 186-192.